evaluation of the clinical efficacy of 1.2% atorvastatin in the treatment of periodontal intraosseous defects by cbct: a randomized controlled clinical trial

Background. atorvastatin (atv), which belongs to the statin class of drugs, is the formidable inhibitor of 3-hydroxy-2- methyl-glutaryl coenzyme a reductase. this clinical trial evaluated and compared the clinical and radiographic changes in chronic periodontitis (cp) patients, obtained through 1.2% atv as an adjunct to scaling and root planing (srp) in the treatment of intraosseous defects. methods. twenty cp patients, with a minimum of one pair of bilateral intraosseous, were randomly selected for this splitmouth study. group 1 included 20 sites treated with srp and subgingival delivery of a placebo gel, whereas an equal number of sites in group 2 were treated by srp along with subgingival delivery of 1.2% atv gel. the plaque index (pi), modified sulcus bleeding index (msbi), probing pocket depth (ppd) and clinical attachment level (cal) were evaluated at baseline and 3 and 6-month intervals, while the intraosseous defect was assessed at baseline and 6month interval using conebeam computed tomography (cbct). paired ttest was used to determine statistical significance. results. a greater reduction in the mean ppd and gain in cal was found in group 2 compared to group 1 at 3 and 6month intervals. furthermore, a significantly greater bone fill was obtained in group 2 (1.70±0.54 mm) compared to group 1 (0.22±0.43 mm) after six months. conclusion. atv, as an adjunct to srp, enhanced periodontal regeneration, as a noninvasive way to treat periodontal intraosseous defects.